SecBot SecBot

KPTI

Karyopharm Therapeutics Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001503802 Biotech & Drug Discovery
$0.0250 −0.00 (−3.85%)
Nov 13 4:00 PM ET · prev $0.0260
Market cap
$907.3K
Nano cap
Consensus
Buy
82% Buy or better · 11 analysts
Median target
$7.00
+27900% · range $3.00–11.00
1 year
−99.6%
from $5.79 · Nov 17
30 days
−92.8%
from $0.3460
52-week range
$0.0170–10.67
−100% from high · low Nov 10
Avg volume 20D
24.64M
Nov 10 spike 146.82M
Short interest
8.23M
≈36.3% of shares · +13.3%
Days to cover
1.1
at average volume
Insider net
−$298.2K
0 buyers · 7 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 1 exit
Filing reports
30
analyzed by SecBot
SecBot read BEARISH 15 reports · 90 days
Balance 8 bearish · 1 bullish · 6 neutral oldest → newest, height = score
Avg score ·High conf. 11/15

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    7 insiders sold $298.2K.

  • InstitutionsBULLISH

    Q3 2026: 7 added (0 new), 2 trimmed or exited.

  • AnalystsBULLISH

    9 of 11 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$1.457 → −$1.050 over 90 days. 1 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest +13.3% to 8.23M shares. 1.1 days to cover, ≈36.3% of shares.

  • TrendDOWNTREND

    97% below its 50-day average. New closing low $0.0170 on Nov 10.

  • SocialQUIET

    No Reddit mentions this week. Last mention Nov 6.

Who's buying

13F· Q3 2026
0
new positions
1
exit
FundMoveSharesValue
UBS Group AGDOUBLED963,891$1.2M
FMR LLCDOUBLED240,312$293.2K
SIMPLEX TRADING, LLCDOUBLED69,837$85.2K
Nuveen, LLCADD65,578$80.0K
RHUMBLINE ADVISERSADD30,772$37.5K
BARCLAYS PLCNEAR_EXIT28,739$35.1K
SEI INVESTMENTS COADD21,436$26.1K
Russell Investments Group, Ltd.DOUBLED6,789$8.3K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

11 analysts
Buy 82% rate it Buy or better
Strong Buy3Buy6Hold2Sell0Strong Sell0
12-month targets · 2 analysts

Price is below the lowest target. Median implies +27900%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 2, 2026Rodman & Renshaw
DOWNGRADE
DOWNGRADENeutral
Jul 31, 2026Piper Sandler
MAINTAIN
MAINTAINOverweight
Jul 31, 2026HC Wainwright & Co.
DOWNGRADE
DOWNGRADENeutral
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent
Nov 17, 2026
Earnings date
🔒 Fresh data, subscribers only
Nov 11, 2026
Listing
Delisted: KPTI, removed from the Nasdaq symbol directory
Karyopharm Therapeutics Inc. - Common Stock
Nov 4, 2026
Company news
Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH)
Week 48 Data from the Phase 3 SENTRY Trial Selected for Oral Presentation, – Data from the Phase 2 SENTRY-2 Trial Selected for Oral Presentation…
Nov 2, 2026
Trading halt
Halt Resumed: KPTI, trading resumed after T3 (News and Resumption Times)
Halted 2026-11-02T12:07:00.000Z | Resumed 2026-11-02T12:40:00.000Z
Nov 2, 2026
Trading halt
Trading Halt: KPTI · T1 (News Pending)
Karyopharm Therapeutics Inc. | Market: NASDAQ | Code: T1 (News Pending)

Insider ledger

Form 4
$0
bought · 0 insiders
$298.2K
sold · 7 insiders
DateInsiderTypeValue
Oct 16, 2026
Abate Kristin
Chief Accounting Officer
Oct 16, 2026
SELL$1.6K
Oct 1, 2026
Abate Kristin
Chief Accounting Officer
Oct 1, 2026
SELL$449.82
Sep 1, 2026
Abate Kristin
Chief Accounting Officer
Sep 1, 2026
SELL$38.38
Jul 28, 2026
Poulton Stuart
EVP, Chief Development Officer
Jul 28, 2026
SELL$1.3K
May 21, 2026
Greene Barry E
Director
May 21, 2026
AWARD15,508 sh
May 21, 2026
Su Zhen
Director
May 21, 2026
AWARD15,508 sh
May 21, 2026
Schor Chen
Director
May 21, 2026
AWARD15,508 sh
May 21, 2026
Oliger Christy J.
Director
May 21, 2026
AWARD15,508 sh

Earnings setup

Estimates
−$1.05
EPS estimate, this quarter
+28%
estimate change, 90 days
1↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.05-$1.05–-$1.05+14.4%$33.1M
Next Q🔒 Fresh data, subscribers only
Current FY-$4.10-$4.10–-$4.10+22.1%$134.4M
Next FY-$1.72-$2.50–-$0.94+27.9%$159.9M

Washington

Corporate Lobbying

6 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
8,232,156
shares short
+13.3%
vs prior settlement
1.1
days to cover
≈36.3%
of shares outstanding
Trading halts
Nov 2, 2026Resumption ScheduledResumed
Jul 30, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 17, 2026 Earnings calendar
🔒 Fresh data, subscribers only
Nov 13, 2026 SEC
Affinity Asset Advisors and Michael Cho filed an amended Schedule 13G disclosing a new passive stake of 1,573,517…
SC 13G/A · Impact 3/10
Nov 13, 2026 SEC
Karyopharm Therapeutics filed an NT 10-Q stating it cannot timely file its Q3 2026 10-Q due to the time and resource…
NT 10-Q · Impact 7/10
Nov 12, 2026 SEC
Adage Capital Management filed an amended Schedule 13G disclosing a beneficial ownership of 2,013,106 shares (8.87%)…
SC 13G/A · Impact 3/10
Oct 16, 2026 Insider
Abate Kristin sold 4,788 shares
Chief Accounting Officer @ $0.3440 ($1.6K)
Oct 1, 2026 Insider
Abate Kristin sold 378 shares
Chief Accounting Officer @ $1.19 ($449.82)
Sep 30, 2026 Inst.
UBS Group AG · DOUBLED
963,891 shares ($1.2M)
Sep 30, 2026 Inst.
FMR LLC · DOUBLED
240,312 shares ($293.2K)
Reddit Mentions per day, 14 days
Recent posts
All social signals and their track records

SecBot reports

30 filings · 1 bullish · 14 bearish · 2 mixed · 13 neutral
All KPTI filing & press-release reports (30)